Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by BayStreetWildon Feb 07, 2023 2:39pm
118 Views
Post# 35272504

RE:I wouldn't want...

RE:I wouldn't want...

any second now. October 14


mercedesman wrote: ...to miss the opportunity to buy cheap shares before the :


1) closing of the financing (often a bounce when done)

2) announcement (or "leak") of the secret & largest "partner" on the DIMI useability Trial.

3) announcement of the first patient enrollment into the DIMI usablitily Trial (start the count-down)

4) any announcement of an acceleration of Tigris enrollment (expected for this fall due to improved ICU capacities, flu patient prosepcts,  additional sites ).  Market would then anticipate tranche # 2 form Baxter, and possibly $ form future warrant exercising.  Possibly negates need for future financings

5) elucidation of the "strategic partner"  that is taking an equity stake for the first time (see debenture financing)

6) confirmation of how full the coffers are looking - post financing.  De-risked from a cash flow perspective.  Was the raise fully (over?) subscribed ?

7) any new ARC or VA orders/sales (worst case evidenced in Qtrly filings).  Offsets need for future financing.

8) possible partial monetization of Dialco in the ST.  Will it add cash or marketable securities?  Will it improve EDT SP?


MM

 

<< Previous
Bullboard Posts
Next >>